IL107003A0 - 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man - Google Patents

3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man

Info

Publication number
IL107003A0
IL107003A0 IL107003A IL10700393A IL107003A0 IL 107003 A0 IL107003 A0 IL 107003A0 IL 107003 A IL107003 A IL 107003A IL 10700393 A IL10700393 A IL 10700393A IL 107003 A0 IL107003 A0 IL 107003A0
Authority
IL
Israel
Prior art keywords
pyrrolo
disubstituted
dihydro
heterocyclic
man
Prior art date
Application number
IL107003A
Other languages
English (en)
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of IL107003A0 publication Critical patent/IL107003A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL107003A 1992-09-18 1993-09-14 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man IL107003A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/947,152 US5278162A (en) 1992-09-18 1992-09-18 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Publications (1)

Publication Number Publication Date
IL107003A0 true IL107003A0 (en) 1993-12-28

Family

ID=25485622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL107003A IL107003A0 (en) 1992-09-18 1993-09-14 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man

Country Status (10)

Country Link
US (1) US5278162A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0660833A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH08501550A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1094406A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU4856893A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2144636A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL107003A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW248560B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994006793A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA936872B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296478A (en) * 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
WO1995029909A1 (en) * 1994-04-29 1995-11-09 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
RU2009117642A (ru) * 2006-10-12 2010-11-20 Ксенон Фармасьютикалз Инк. (Ca) Применение спирооксиндоловых соединений в качестве терапевтических средств
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
MX2011004055A (es) 2008-10-17 2011-06-24 Xenon Pharmaceuticals Inc Compuestos de espiro-oxindol y su uso como agentes terapeuticos.
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
ES2467166T3 (es) * 2009-10-14 2014-06-12 Xenon Pharmaceuticals Inc. Métodos de síntesis de compuestos de espiro-oxindol
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
JP2013521232A (ja) 2010-02-26 2013-06-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
AU3776589A (en) * 1988-06-14 1990-01-12 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones

Also Published As

Publication number Publication date
CN1094406A (zh) 1994-11-02
ZA936872B (en) 1995-03-17
CA2144636A1 (en) 1994-03-31
EP0660833A1 (en) 1995-07-05
US5278162A (en) 1994-01-11
AU4856893A (en) 1994-04-12
JPH08501550A (ja) 1996-02-20
WO1994006793A1 (en) 1994-03-31
TW248560B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-06-01

Similar Documents

Publication Publication Date Title
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
IL107003A0 (en) 3,3'-disubstituted-1,3-dihydro-2h-pyrrolo(2,3,-b)heterocyclic-2-one useful in the treatment of cognitive disorders of man
ZA904991B (en) 5,11-dihydro-6h-dipyrido(3,2-b:2',3'-e)(1,4)-diazepin-6-ones and-thiones and their use for the treatment of aids
GB9226860D0 (en) Novel treatment
FI943765A7 (fi) 4-aminopyridiinin käyttö neurologisen tilan hoidossa
GB9211148D0 (en) Novel treatment
GB9203039D0 (en) Treatment
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
ZA931063B (en) Treatment of glaucoma.
GB9226958D0 (en) Produktionsaktieselskab) novel treatment
SG47098A1 (en) Diamines in the treatment of arrhythmia
GB9214373D0 (en) Newadjustable "photo-back"
GB2282529B (en) Baby's bath
GB9203637D0 (en) Novel treatment
ZA936874B (en) Process for the preparation of 5,6-diacetoxyindole
ZA937604B (en) 3,3-disubstituted tri and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
EP0579077A3 (en) 1,3,4-thiadiazinones for the treatment of cardiovascular diseases
GB9607420D0 (en) Formulations of mannose phosphates useful in the treatment of fibrotic disorders
IL100629A0 (en) Apparatus for the treatment of papulosquamous disorders
GB9220588D0 (en) The "trailersafe"
GB9204036D0 (en) The"secura-grip"
CA70342S (en) Surgeon's hood
AU115212S (en) Child's changing unit
GB9028228D0 (en) Kiln's pollution treatment
IE891758L (en) Therapeutic uses of 2', 5'-oligoadenylates